期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

^(18)F-FDG SPECT/CT检查结合CA15-3检测在乳腺癌术后复发转移诊断中的价值 被引量：1

下载PDF
导出
摘要 目的探讨18F-FDG SPECT/CT检查结合CA15-3检测在乳腺癌术后复发病例的早期诊断价值。方法对62例乳腺癌术后病例同时进行18F-FDG SPECT/CT检查和CA15-3检测,怀疑复发病例进行CT增强扫描和临床随访,以进一步确诊。结果 62例患者中,18F-FDG SPECT/CT检查发现核素异常浓聚19例,经CT增强扫描和临床资料证实为转移灶12例,阳性率和假阳性率分别为19.4%,11.3%,特异性为86.0%。本组病例CA15-3升高8例,证实为转移灶病例中CA15-3升高6例,阳性率和假阳性率分别为9.8%,3.2%,特异性96.4%。结论 18F-FDG SPECT/CT检查和CA15-3检测是乳腺癌术后复发的可靠检查方法。统计分析表明,18F-FDG SPECT/CT检查异常显著高于CA15-3升高,提示18F-FDG SPECT/CT检查是乳腺癌术后复发的较好方法,18F-FDG SPECT/CT检查结合CA15-3检测可以提高乳腺癌术后转移的诊断率和准确性,在乳腺癌术后复查时联合应用具有重要意义。
作者 贾晓娟 韩军 李慧 曾强生 许泽清
机构地区 广东省珠海市中山大学附属第五医院核医学科 广东省珠海市中山大学附属第五医院化疗科
出处 《中国实用医药》 2010年第18期117-118,共2页 China Practical Medicine
关键词 乳腺癌 复发 18F-FDG SPECT/CT CA15-3
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1Price P.Position emission Tomography(PET) in diagnostic oncology:is it a necessary tool today? Eur-J-cancer,2000,36:69.
  • 2董孟杰,林祥通,赵军.PET-CT在卵巢癌中的临床应用价值[J].国外医学（放射医学核医学分册）,2005,29(5):209-213. 被引量：7
  • 3孙燕.肿瘤标志物在临床上的应用//孙燕.内科肿瘤学,2003:365.
  • 4Bender H,Kirst J,Palmedo H,et al.Value of 18-fluoro-deoxyglucose positron emission tomography in the staging if recurrent breast carcinoma.Anticancer Res,1997,17:1687.
  • 5Moon DP,Maddahi J,Silverman DHS,et al.Accuracy of whole-body fluorine 18-FDG PET for the detection of recurrent or metastatic breast carcinoma.J Nncl Med,1998,39:431.
  • 6Bombardieri E,Crippa F,Baio SM,et al.Nuclear Medicine advances in breast cancer imaging.Tumori,2001,87:277.
  • 7Charron M,Beyer T,Bohnen NN,et al.Image analysis in patients with cancer studied with a combined PET and CT scanner.Clin Nucl Med,2000,25:905.

二级参考文献19

  • 1Rose PG, Faulhaber P, Miraldi F, et al. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy [J]. Gynecol Oncol, 2001, 82(1): 17-21.
  • 2Zimny M, Siggelkow W, Schroder W, et al. 2-[Fluorine-18]-fluoro2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer [J]. Gynecol Oncol, 2001, 83(2): 310-315.
  • 3Miller TR, Grigsby PW. Measurement oftumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treat-ed by radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2002, 53(2): 353-359.
  • 4Barranger E, Kerrou K, Petegnief Y. Laparoscopic resection of occult metastasis using the combination of FDG-positron emission tomography/computed tomography image fusion with intraoperative probe guidance in a woman with recurrent ovarian cancer[J]. Gynecol Oncol, 2005, 96(1): 241-244.
  • 5Smith GT, Hubner KF, McDonald T, et al. Cost analysis of FDG PET for managing patients with ovarian cancer[J]. Clin Positron Imaging, 1999, 2(2): 63-70.
  • 6Kurokawa T, Yoshida Y, Kawahara K, et al. Expression of GLUT-1glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fiuorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary[J]. Int J Cancer,2004, 109(6): 926-932.
  • 7Torizuka T, Kanno T, Futatsubashi M, et al. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET[J].J Nucl Med,2003, 44(7): 1051-1056.
  • 8Robinson MK, Doss M, Shaller C, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine- 124 labeled anti-HER2 diabody[J]. Cancer Res, 2005,65(4): 1471-1478.
  • 9Nishizawa S, Inubushi M, Okada H. Physiological 18F-FDG uptake in the ovaries and uterus of healthy female volunteers[J]. Eur J Nucl Med Mol Imaging, 2005, 32(5): 549-556.
  • 10Torizuka T, Nobezawa S, Kanno T, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using2[fluorine-18]-fluoro-2-deoxy-D-glucose[J]. Eur J Nucl Med Mol Imaging, 2002, 29(6): 797-803.

共引文献6

同被引文献13

引证文献1

二级引证文献1

中国实用医药
2010年 第18期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部